✦ LIBER ✦

PHASE II TRIAL OF TESMILIFENE PLUS MITOXANTRONE AND PREDNISONE FOR HORMONE REFRACTORY PROSTATE CANCER: HIGH SUBJECTIVE AND OBJECTIVE RESPONSE IN PATIENTS WITH SYMPTOMATIC METASTASES

✍ Scribed by RAGHAVAN, D.; BRANDES, L.J.; KLAPP, K.; SNYDER, T.; STYLES, E.; TSAO-WEI, D.; LIESKOVSKY, G.; QUINN, D.I.; RAMSEY, E.W.

Book ID: 122457983
Publisher: Lippincott Williams and Wilkins
Year: 2005
Tongue: English
Weight: 87 KB
Volume: 174
Category: Article
ISSN: 0022-5347
DOI: 10.1097/01.ju.0000176799.63184.99

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase III Study of Mitoxantrone Plus Low

Phase III Study of Mitoxantrone Plus Low Dose Prednisone Versus Low Dose Prednisone Alone in Patients With Asymptomatic Hormone Refractory Prostate Cancer

✍ BERRY, WILLIAM; DAKHIL, SHAKER; MODIANO, MANUEL; GREGURICH, MARYANN; ASMAR, LINA 📂 Article 📅 2002 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 82 KB

Phase II Trial of Gemcitabine, Prednison

Phase II Trial of Gemcitabine, Prednisone, and Zoledronic Acid in Pretreated Patients with Hormone Refractory Prostate Cancer

✍ Giuseppe Di Lorenzo; Riccardo Autorino; Mario Giuliano; Emilio Morelli; Antonio 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 83 KB

Phase II randomised trial of docetaxel (

Phase II randomised trial of docetaxel (D), estramustine (E) and prednisone (P) — Two schedules — versus mitoxantrone (M) and prednisone in patients (PTS) with hormone refractory prostate cancer (HRPC)

✍ S. Qudard; E.B. Banu; E. Voog; H. Hardy-Bessard; C. Linassier; P. Beuzeuboe; A. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 187 KB

Phase II trial of anti-idiotypic p53 pep

Phase II trial of anti-idiotypic p53 peptides (Pentrys) plus granulocyte-macrophage colony-stimulating factor in patients with hormone-refractory prostate cancer

✍ Ian D DAVIS; Guy TONER; Adam BROAD; Louise M CAMPANO; Mark ROSENTHAL 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 171 KB

7013 Phase II trial of the specific endo

7013 Phase II trial of the specific endothelin A receptor antagonist zibotentan (ZD4054) in pain-free or mildly symptomatic patients with hormone-resistant prostate cancer and bone metastases: final analysis of safety and efficacy

✍ James, N.D.; Morris, T.; Phung, D.; McIntosh, S.; Dawson, N.A. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

385 A phase II trial to assess the effic

385 A phase II trial to assess the efficacy and safety of gefitinib (Iressa™) in patients with metastatic hormone refractory prostate cancer (HRPC) who progressed on treatment with a luteinising hormone releasing hormone analogue (or post orchiectomy) plus an antiandrogen

✍ G. Curigliano; O. De Cobelli; M.T. Sandri; L. Zorzino; C. Noberasco; T. De Pas; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 292 KB